|Articles|June 10, 2015
- Precision Medicine
- Volume 2
- Issue 1
Significance of the NCI Molecular Analysis for Therapy Choice Program
Author(s)Jonathan C. Trent, MD, PhD
Jonathan C. Trent, MD, PhD, professor of medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, gives an overview of the NCI Molecular Analysis for Therapy Choice Program (MATCH).
Jonathan C. Trent, MD, PhD, professor of medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, gives an overview of the NCI Molecular Analysis for Therapy Choice Program (MATCH).
<<<
Articles in this issue
almost 11 years ago
Early Detection of Resistance in Lung Cancer Detected Through ctDNA in Urinealmost 11 years ago
Nivolumab and Future Biomarkers in NSCLCalmost 11 years ago
Screening Needed for Younger Breast Cancer Patients Based on Mutation Yieldalmost 11 years ago
Clinical Validation and Utility of a Liquid Biopsy in NSCLCalmost 11 years ago
Scoring System May Help Guide Therapy in Triple-Negative Breast CancerRelated Content
Advertisement
